A trend toward a higher ORR was seen in patients with PDL1-positive vs. PDL1-negative tumor-associated immune cells in the overall population (16.7% vs. 1.6%) and in the TNBC subgroup (22.2% vs. 2.6%) (34). This evidence concerns the gene CD274 and neoplasm.